Business Context and Reporting Period
This Form 8-K Current Report was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on February 17, 2015. The filing discloses a significant capital market transaction involving the pricing of senior notes and details the intended use of proceeds to finance a strategic acquisition.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company priced $500 million of 3.250% Senior Notes due March 1, 2025, and $500 million of 4.250% Senior Notes due March 1, 2045.
- Total Principal: $1.0 billion aggregate principal amount.
- Net Proceeds: Estimated at approximately $987 million after deducting underwriting discounts and offering expenses.
- Use of Proceeds: Intended to finance a portion of the proposed acquisition of MWI Veterinary Supply, Inc. (MWI), pay related fees, and retire outstanding MWI indebtedness.
- Liquidity Status: As of February 12, 2015, there were no borrowings outstanding under the Company's Multi-Currency Revolving Credit Facility.
Material Changes and Transaction Terms
The primary material change is the execution of an Underwriting Agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated and Wells Fargo Securities, LLC. The sale of the notes is expected to close on February 20, 2015. The notes are senior unsecured obligations. Pending the use of proceeds, the Company intends to invest funds in institutional money market funds, U.S. government securities, or other short-term interest-bearing securities.
Guidance, Risks, and Contingencies
- Acquisition Contingency: The note offering is not contingent on the completion of the MWI acquisition. However, if the acquisition is not completed by May 15, 2015, or if the agreement is terminated prior to that date, the notes are subject to mandatory redemption at 101% of the aggregate principal amount plus accrued interest.
- Underwriter Relationships: The underwriters and their affiliates have extensive existing relationships with the Company, including roles in credit facilities, securitization, and financial advisory services for the MWI acquisition.
- Risk Factors: Forward-looking statements are subject to risks including pharmaceutical market growth rates, price inflation/deflation, regulatory changes, capital market volatility, and integration risks associated with the MWI acquisition.
Investor Verification Checklist
- Verify the closing of the $1.0 billion note offering on or before February 20, 2015.
- Monitor the status of the MWI Veterinary Supply, Inc. acquisition to determine if the mandatory redemption clause (triggered by May 15, 2015) becomes relevant.
- Review the definitive Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification provisions.
- Assess the impact of the new debt load on the Company's leverage ratios and liquidity position post-closing.